A Sola1, J Roselló-Catafau, E Gelpí, G Hotter. 1. Department of Medical Bioanalysis, Instituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC-IDIBAPS), C/Roselló 161, 7(a) planta, Barcelona, Spain.
Abstract
BACKGROUND AND AIMS: Inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by nitric oxide (NO) in intestinal preconditioning could modify the rate of formation of glycolytic intermediates. Fructose-1,6-biphosphate (F16BP) is a glycolytic intermediate that protects tissue from ischaemia/reperfusion injury. We evaluated if F16BP may be endogenously accumulated as a consequence of GAPDH inhibition by NO during intestinal preconditioning in rats. METHODS: We assessed: (1) effect of preconditioning on F16BP content; (2) effect of NO on GAPDH activity before and during sustained ischaemia; and (3) protective effect of F16BP in control, ischaemic, and preconditioned animals with or without administration of N-nitro-L-arginine methyl ester (L-NAME), NO donor, or F16BP. RESULTS: Preconditioned rats showed a significant transient decrease in GAPDH activity and also maintained basal F16BP levels longer than ischaemic rats. L-NAME administration to preconditioned rats reversed these effects. F16BP administration to ischaemic rats decreased protein release in the perfusate. Administration of F16BP to L-NAME treated rats attenuated the harmful effect of L-NAME. CONCLUSIONS: Our study indicates that F16BP may be endogenously accumulated in preconditioned rats as a consequence of inhibition of GAPDH by NO, and this may contribute to the protection observed in intestinal preconditioning.
BACKGROUND AND AIMS: Inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by nitric oxide (NO) in intestinal preconditioning could modify the rate of formation of glycolytic intermediates. Fructose-1,6-biphosphate (F16BP) is a glycolytic intermediate that protects tissue from ischaemia/reperfusion injury. We evaluated if F16BP may be endogenously accumulated as a consequence of GAPDH inhibition by NO during intestinal preconditioning in rats. METHODS: We assessed: (1) effect of preconditioning on F16BP content; (2) effect of NO on GAPDH activity before and during sustained ischaemia; and (3) protective effect of F16BP in control, ischaemic, and preconditioned animals with or without administration of N-nitro-L-arginine methyl ester (L-NAME), NO donor, or F16BP. RESULTS: Preconditioned rats showed a significant transient decrease in GAPDH activity and also maintained basal F16BP levels longer than ischaemic rats. L-NAME administration to preconditioned rats reversed these effects. F16BP administration to ischaemic rats decreased protein release in the perfusate. Administration of F16BP to L-NAME treated rats attenuated the harmful effect of L-NAME. CONCLUSIONS: Our study indicates that F16BP may be endogenously accumulated in preconditioned rats as a consequence of inhibition of GAPDH by NO, and this may contribute to the protection observed in intestinal preconditioning.
Authors: E P Garvey; J A Oplinger; E S Furfine; R J Kiff; F Laszlo; B J Whittle; R G Knowles Journal: J Biol Chem Date: 1997-02-21 Impact factor: 5.157
Authors: G Hotter; D Closa; M Prados; L Fernández-Cruz; N Prats; E Gelpí; J Roselló-Catafau Journal: Biochem Biophys Res Commun Date: 1996-05-06 Impact factor: 3.575
Authors: I Herrero; J Torras; M Carrera; A Castells; L Pasto; S Gil-Vernet; J Alsina; J M Grinyo Journal: Nephrol Dial Transplant Date: 1995 Impact factor: 5.992